ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE and BONE DENSITY DECREASED

Overview

BONE DENSITY DECREASED is the #1 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 4,492 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE to BONE DENSITY DECREASED. This represents approximately 10.4% of all 43,023 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE who experience bone density decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

BONE DENSITY DECREASED is a frequently reported adverse event for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, accounting for a significant proportion of all reports.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

In addition to bone density decreased, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

• CHRONIC KIDNEY DISEASE — 2,605 reports
• BONE LOSS — 2,410 reports
• OSTEONECROSIS — 2,378 reports
• TOOTH LOSS — 2,247 reports
• MULTIPLE FRACTURES — 2,131 reports
• RENAL FAILURE — 2,086 reports
• OSTEOPOROSIS — 1,928 reports
• RENAL INJURY — 1,916 reports
• PAIN — 1,857 reports
• EMOTIONAL DISTRESS — 1,803 reports

Other Drugs Associated with BONE DENSITY DECREASED

The following drugs have also been linked to bone density decreased in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE cause BONE DENSITY DECREASED?

BONE DENSITY DECREASED has been reported as an adverse event in 4,492 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is BONE DENSITY DECREASED with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

BONE DENSITY DECREASED accounts for approximately 10.4% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, making it one of the most commonly reported side effect.

What should I do if I experience BONE DENSITY DECREASED while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

If you experience bone density decreased while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages